Chromosomal microarray analysis is an important diagnostic tool to identify copy number variations (CNV). Some of the CNVs affect susceptibility regions, which means that deletions or duplications in these regions have partial penetrance and often give an increased risk for a spectrum of neurocognitive disorders. Not much is known about the impact of rare CNV susceptibility syndromes on the life of patients or their parents. In this study, we focus on one specific susceptibility CNV disorder, 16p11.2 deletion syndrome. This rare condition is characterised by an increased risk of mild intellectual disability, autism spectrum disorder, epilepsy, and obesity. We aimed to explore the impact of such a disorder on the family members involved in the daily care of children with this syndrome. Three focus group discussions were held with 23 Dutch (grand)parents. Thematic analysis was performed by two independent researchers. The following five themes emerged: (1) the end of a diagnostic odyssey and response to the diagnosis, (2) after the diagnosis—life with a child with 16p11.2 deletion syndrome, (3) access to medical care and support services, (4) nobody knows what 16p11.2 deletion syndrome is, and (5) future perspective—ideal care. The participants experienced a lack of knowledge among involved professionals. Together with the large variability of the syndrome, this led to fragmented care and unfulfilled needs regarding healthcare, social, and/or educational assistance. Care for children with a CNV susceptibility syndrome could be improved by a multidisciplinary approach or central healthcare professional, providing education and information for all involved professionals.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749–64.
Paul JL, Pope-Couston R, Wake S, Burgess T, Tan TY. Communicating microarray results of uncertain clinical significance in consultation summary letters and implications for practice. Eur J Hum Genet. 2016;25:22–30.
Kaminsky EB, Kaul V, Paschall J, Church DM, Bunke B, Kunig D, et al. An evidence-based approach to establish the functional and clinical significance of copy number variants in intellectual and developmental disabilities. Genet Med. 2011;13:777–84.
Vo OK, McNeill A, Vogt KS. The psychosocial impact of 22q11 deletion syndrome on patients and families: a systematic review. Am J Med Genet A. 2018;176:2215–25.
Martin N, Mikhaelian M, Cytrynbaum C, Shuman C, Chitayat DA, Weksberg R, et al. 22q11.2 deletion syndrome: attitudes towards disclosing the risk of psychiatric illness. J Genet Couns. 2012;21:825–34.
Thapar A, Cooper M. Copy number variation: what is it and what has it told us about child psychiatric disorders? J Am Acad Child Adolesc Psychiatry. 2013;52:772–4.
Bijlsma EK, Gijsbers AC, Schuurs-Hoeijmakers JH, van Haeringen A, Fransen van de Putte DE, Anderlid BM, et al. Extending the phenotype of recurrent rearrangements of 16p11.2: deletions in mentally retarded patients without autism and in normal individuals. Eur J Med Genet. 2009;52:77–87.
Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B, Morgen K, Arnarsdottir S, et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature. 2014;505:361–6.
Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med. 2008;358:667–75.
Mei C, Fedorenko E, Amor DJ, Boys A, Hoeflin C, Carew P, et al. Deep phenotyping of speech and language skills in individuals with 16p11.2 deletion. Eur J Hum Genet. 2018;26:676–86.
Miller DT, Chung W, Nasir R, Shen Y, Steinman KJ, Wu BL, et al. 16p11.2 recurrent microdeletion. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle, WA; 1993.
Kitzinger J. Qualitative research. Introducing focus groups. BMJ. 1995;311:299–302.
VERBI Software. MAXQDA analytics Pro 12 ed. Berlin (Germany): VERBI; 2017.
Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3:77–101.
IBM Corporation. SPSS statistics for Windows, version 24.0. Armonk, NY: IBM Corporation; 2016.
Rosenthal ET, Biesecker LG, Biesecker BB. Parental attitudes toward a diagnosis in children with unidentified multiple congenital anomaly syndromes. Am J Med Genet. 2001;103:106–14.
Reiff M, Bernhardt BA, Mulchandani S, Soucier D, Cornell D, Pyeritz RE, et al. “What does it mean?”: uncertainties in understanding results of chromosomal microarray testing. Genet Med. 2012;14:250–8.
Reiff M, Ross K, Mulchandani S, Propert KJ, Pyeritz RE, Spinner NB, et al. Physicians’ perspectives on the uncertainties and implications of chromosomal microarray testing of children and families. Clin Genet. 2013;83:23–30.
Cardinali P, Migliorini L, Rania N. The caregiving experiences of fathers and mothers of children with rare diseases in italy: challenges and social support perceptions. Front Psychol. 2019;10:1780.
Baumbusch J, Mayer S, Sloan-Yip I. Alone in a Crowd? Parents of children with rare diseases’ experiences of navigating the healthcare system. J Genet Couns. 2019;28:80–90.
Turnpenny P, Smith R. Of eponyms, acronyms and…orthonyms. Nat Rev Genet. 2003;4:152–6.
Smith J, Cheater F, Bekker H. Parents’ experiences of living with a child with a long-term condition: a rapid structured review of the literature. Health Expect. 2015;18:452–74.
Hennekam RC. Care for patients with ultra-rare disorders. Eur J Med Genet. 2011;54:220–4.
We would like to thank all the participants of the focus group interviews. We thank Saskia Kleinendorst for the transcriptions and Mellody Cooiman for her help during the focus group sessions.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kleinendorst, L., van den Heuvel, L.M., Henneman, L. et al. Who ever heard of 16p11.2 deletion syndrome? Parents’ perspectives on a susceptibility copy number variation syndrome. Eur J Hum Genet 28, 1196–1204 (2020). https://doi.org/10.1038/s41431-020-0644-6